Robeco Institutional Asset Management B.V. Purchases 8,947 Shares of Davita Inc (DVA)
Robeco Institutional Asset Management B.V. grew its position in shares of Davita Inc (NYSE:DVA) by 7.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,903 shares of the company’s stock after acquiring an additional 8,947 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.08% of Davita worth $9,592,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Davita during the second quarter valued at approximately $206,000. Green Square Capital LLC bought a new stake in shares of Davita during the second quarter valued at approximately $208,000. IFG Advisory LLC bought a new stake in shares of Davita during the second quarter valued at approximately $213,000. Seven Eight Capital LP bought a new stake in shares of Davita during the third quarter valued at approximately $219,000. Finally, Atria Investments LLC bought a new stake in shares of Davita during the second quarter valued at approximately $243,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.
DVA has been the subject of several recent research reports. Zacks Investment Research downgraded Davita from a “hold” rating to a “sell” rating in a report on Tuesday, November 13th. ValuEngine downgraded Davita from a “buy” rating to a “hold” rating in a report on Wednesday, October 17th. UBS Group initiated coverage on Davita in a report on Thursday. They set a “sell” rating and a $64.00 price objective for the company. TheStreet downgraded Davita from a “b-” rating to a “c+” rating in a report on Thursday, November 8th. Finally, JPMorgan Chase & Co. upgraded Davita from an “underweight” rating to a “neutral” rating in a report on Thursday, September 13th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $82.44.
Davita (NYSE:DVA) last announced its quarterly earnings results on Wednesday, November 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.89 by ($0.33). Davita had a return on equity of 13.87% and a net margin of 5.39%. The company had revenue of $2.85 billion for the quarter, compared to the consensus estimate of $2.93 billion. During the same quarter last year, the company posted $0.81 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, equities analysts anticipate that Davita Inc will post 3.56 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2018/11/19/robeco-institutional-asset-management-b-v-purchases-8947-shares-of-davita-inc-dva.html.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.